PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2012; 01(02): 53-55
DOI: 10.4103/2278-330X.103707
Mini Symposium on Changing Landscape: Editorial

The changing landscape of hormonal therapy in castration-resistant prostate cancer

Amol Dongre
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
,
Kumar Prabhash
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
,
Vanita Noronha
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
› Institutsangaben Source of Support: Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
30. Dezember 2020

© 2012. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • 1 Schröder FH. Pure antiandrogens as monotherapy in prospective studies of prostatic carcinoma. Prog Clin Biol Res 1990;359:93-103.
  • 2 Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993;11:2167-72.
  • 3 Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33.
  • 4 Sartor AO, Tangen CM, Hussain MH, Eisenberger MA, Parab M, Fontana JA, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9426). Cancer 2008;112:2393-400.
  • 5 Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-7.
  • 6 Labrie F, Dupont A, Giguere M, Borsanyi JP, Lacourciere Y, Monfette G, et al. Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 1988;61:341-6.
  • 7 Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008;180:921-7.
  • 8 Manikandan R, Srirangam SJ, Pearson E, Brown SC, O′Reilly P, Collins GN. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: A prospective randomized trial. Urol Int 2005;75:217-21.
  • 9 Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 2004;22:1025-33.
  • 10 Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
  • 11 Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13:983-92.
  • 12 Ryan CJ, Smith MR, De Bono JS, Molina A, Logothetis C, De Souza PL, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2012;3.
  • 13 Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010;375:1437-46.
  • 14 Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97.